This is the authors' abstract. We don't add key points for this paper.
BC Risk, Genetics, and PreventionTesting for BC risk genes can inform about a possible medical and/or surgical therapy for patients but also direct prevention and early detection for healthy individuals.In the therapeutic setting, genetic germline testing for BRCA1, BRCA2 can inform about a possible therapy with PARP inhibitors (according to the label) in the early and advanced BC setting (LoE 1a/A/AGO++).
No takes yet. Share an insight, caveat, or question.
Park-Simon et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: